Jonathan Chang
Stock Analyst at Leerink Partners
(0.57)
# 4,161
Out of 5,115 analysts
76
Total ratings
28.57%
Success rate
-21.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $7.03 | +84.92% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $16.60 | +351.81% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $32.63 | -17.25% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $32.55 | +127.34% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $21.00 | -47.62% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.40 | +311.29% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.52 | +1,050.31% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $6.42 | +678.82% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $96.95 | -69.06% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.83 | +555.74% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $9.55 | +172.25% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.12 | +244.83% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $12.09 | +338.38% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $7.03
Upside: +84.92%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $16.60
Upside: +351.81%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $32.63
Upside: -17.25%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $32.55
Upside: +127.34%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $21.00
Upside: -47.62%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.40
Upside: +311.29%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.52
Upside: +1,050.31%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $6.42
Upside: +678.82%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $96.95
Upside: -69.06%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.83
Upside: +555.74%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.55
Upside: +172.25%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.12
Upside: +244.83%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $12.09
Upside: +338.38%